Carolina Tennyson, assistant professor, contributed to "Sodium–Glucose Cotransporter-2 Inhibitors for Heart Failure: The New Kid on the Block" for The Journal for Nurse Practitioners. Jaime McDermott and Elizabeth Bell-McClure with Duke University Hospital are the article's other authors.

The purpose of this manuscript is to educate nurse practitioners about the evidence, mechanism of action, and prescribing considerations for the SGLT2i medication class when caring for patients with heart failure.

Abstract

Sodium–glucose cotransporter-2 (SGLT2) inhibitors recently emerged as an effective therapy for heart failure (HF) with reduced ejection fraction. Recent published clinical trials have confirmed these agents substantially reduce mortality and HF hospitalization among patients with established HF with reduced ejection fraction, with or without type 2 diabetes. Ongoing studies are evaluating the effects of SGLT2 inhibitors on clinical outcomes for patients with HF with preserved ejection fraction. Nurse practitioners must understand the indications and mechanisms of SGLT2 inhibitors when prescribing. Thoughtful collaboration between cardiology and endocrine providers can guide management with the use of SGLT2 inhibitors in complicated HF patients.

Citation

Jaime McDermott, Carolina Tennyson, Elizabeth Bell-McClure, Sodium–Glucose Cotransporter-2 Inhibitors for Heart Failure: The New Kid on the Block, The Journal for Nurse Practitioners, 2021, ISSN 1555-4155, https://doi.org/10.1016/j.nurpra.2021.02.008.